Dry Eye Clinical Trial - Clinical Efficacy of Topical Hydrocortisone

Status Completed

Clinical Trial Summary

Dry eye disease (DED) is a highly prevalent ocular condition and induces a significant burden to the affected patients. Regardless of the underlying etiology, DED is associated with increased inflammation of the entire ocular surface including the adnexa, conjunctiva and cornea. As such, there is evidence from in vitro, animal and clinical studies that this inflammatory response of the ocular surface plays a pathophysiological key role in the development of DED. The Dry Eye Workshop 2007 (DEWS) therefore suggests the use of anti-inflammatory drugs such as corticosteroids, cyclosporine or others when topical lubricants alone are not sufficient. Recently, Softacort® eye drops containing 0.335% hydrocortisone have gained marketing authorization for the treatment of ocular surface inflammation. This formulation offers several advantages that make them potentially interesting for the treatment of DED. First, the formulation is preservative-free, which is of special importance in patients with DED, since it has been shown that preservatives are detrimental for the ocular surface. Further, hydrocortisone has the advantage that in comparison to other glucocorticoid derivatives, it features poor solubility. This means that corneal penetration is low, which is a desired effect in the treatment of ocular surface inflammation. Because of the poor penetration through thecornea, elevation of intraocular pressure and cataract formation, which are common side effect of corticosteroid treatment, have not been observed with Softacort® to date, also favoring the use of this agent in DED. The aim of the present study is to investigate whether treatment with Softacort® improves ocular surface inflammation as well as clinical signs and symptoms associated with DED in patients who are already taking topical lubricants for at least three months.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03907865
Study type	Interventional
Source	Medical University of Vienna
Contact
Status	Completed
Phase	Phase 4
Start date	March 27, 2018
Completion date	January 2, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05027087` - The Effect of a Novel Blueberry Supplement on Dry Eye Disease	Phase 3
Completed	`NCT05102409` - An Exploratory Clinical Trial to Assess Safety and Tolerability in Subjects With Dry Eye Disease	Phase 2
Completed	`NCT06159569` - Performance and Tolerability of the Medical Device LACRIACT	N/A
Completed	`NCT04081610` - Clinical Trial to Evaluate the Safety and Tolerability of Lagricel® Ofteno Multi-dose Ophthalmic Solution	Phase 1
Completed	`NCT05062564` - Efficacy of LipiFlow in Patients Affected by Meibomian Gland Dysfunction in Reducing Post-cataract Surgery Dry Eye	N/A
Completed	`NCT05825599` - PMCF Study to Evaluate Performance and Safety of "HPMC-based Eyedrops" Used to Relieve Dry Eye Symptoms	N/A
Completed	`NCT03418727` - Dry Eye Disease Study With Brimonidine	Phase 2
Active, not recruiting	`NCT04425551` - Effect of Micropulse Laser on Dry Eye Disease Due to Meibomian Gland Dysfunction	N/A
Recruiting	`NCT04527887` - Intracanalicular Dexamethasone Insert for the Treatment of Inflammation and Discomfort in Dry Eye Disease (DEcIDED)	Phase 4
Not yet recruiting	`NCT06379685` - Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.	Phase 1
Active, not recruiting	`NCT05618730` - Safety, Tolerability, Plug Retention and Preliminary Efficacy of Tacrolimus-loaded Punctal Plug in Patients With Moderate to Severe Dry Eye Disease - Cohort B	Phase 1
Completed	`NCT04553432` - Dry Eye OmniLenz Application of Omnigen Research Study	Phase 4
Recruiting	`NCT04109170` - Dry Eye Evaluation System Based on Bioinformatics
Completed	`NCT04105842` - Refitting Daily Disposable Contact Lens Wearers With Dry Eye Disease With A Different Daily Disposable Lens Type	N/A
Completed	`NCT05505292` - Lifitegrast 5% for the Treatment of Dry Eye In Habitual Soft Contact Lens Wearers	Phase 4
Completed	`NCT04668131` - Study on Curative Effect and Mechanism of Acupuncture on Neuropathic Pain in Dry Eye Disease	N/A
Completed	`NCT06176651` - Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers	Phase 4
Not yet recruiting	`NCT05965778` - Comparison of the Performance and Safety of T2769 Versus Vismed® Multi in the Treatment of Moderate to Severe Dry Eye Syndrome	N/A
Not yet recruiting	`NCT02218827` - Topical Steroid Treatment For Dry Eye	N/A
Completed	`NCT02235259` - Efficacy and Safety of XG-104 for the Treatment of Dry Eye	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Efficacy of Topical Hydrocortisone 0.335% (Softacort®) in Patients With Chronic Dry Eye Disease and Associated Ocular Surface Inflammation

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms